Company news: Wolters Kluwer, NEJM; Teva

Share this article:

The New England Journal of Medicine and Wolters Kluwer Health have signed and agreement that makes the Ovid research platform the exclusive medical aggregator of current non-embargoed NEJM content. Subscribers will also be able to tap into PDFs from 1990 onwards. The previous agreement was HTML access to issues beginning in 1993.

Teva Pharmaceuticals said it closed out the quarter with a 28% increase in sales, to $5.4 billion, compared with $4.4 billion for the same period in 2010. The world's biggest maker of generics said generic sales rose 12% during the quarter, to $3 billion, compared with $2.7 billion in 2010. US generic sales fell 5% but was somewhat offset by a 3% gain in Europe. Branded drug sales rose 68%, to $2.3 billion, compared to $1.3 billion in the fourth quarter of 2010. The company said profit rose 23% during the quarter, reported Bloomberg. Teva bolstered its portfolio in 2011 when it bought Cephalon for $6.8 billion. The purchase added 20 products to the company's footprint as well as entered an OTC agreement with giant Proctor and Gamble.

Share this article:
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

Avastin pockets another Priority Review label

It's the second for this cancer drug in two weeks.

Miss Idaho shows off diabetes pump

NPR reports that the move has made Sierra Sandison a type 1 diabetes hero and that users have given the Facebook photo over 4,000 "likes."

Roche is hungry, not starving for M&A

CEO Severin Schwan tells Reuters that the Swiss firm will be looking for small acquisitions and partnerships.